Literature Archives

Thoracentesis is the more cost-effective initial approach for cancers with pleural fluid cytology sensitivity greater than 27 percent, whereas medical thoracoscopy becomes more cost-effective for recurrent effusions following a negative thoracentesis.

For interventional pulmonologists, X-ray Velocimetry shows strong discriminative ability for pre-procedural collateral ventilation risk stratification with an AUC of 0.862 (P = 0.002), though it cannot yet replace intraoperative Chartis testing due to modest sensitivity.

Transbronchial cryobiopsy using a 1.1-mm probe through a therapeutic bronchoscope is safe and feasible, achieving an 87.5% overall diagnostic yield with significantly larger tissue samples than forceps biopsy and a 95.8% multiplex genetic testing success rate.

Clinicians can now use the newly derived RED score—incorporating baseline respiratory rate, ultrasound effusion depth, and dyspnoea—to predict time to the next procedure, yielding areas under the receiver operator curve of 0.73 and 0.75 in the derivation cohort.

Provides robust, multicenter prospective data supporting the clinical utility and safety of robotic bronchoscopy for peripheral pulmonary lesions.

Omitting patient rotation during doxycycline pleurodesis demonstrated identical 1-month success rates of 85% compared to the rotation group, supporting a simplified protocol to reduce patient burden.

Galaxy robotic bronchoscopy achieved a higher strict diagnostic yield than LungVision (87.6% versus 74.7%; OR 2.40, 95% CI 1.10-5.24; P = 0.03), though success was primarily driven by real-time imaging and tool-lesion alignment rather than platform type or breath-hold utilization.

Bronchoscopic intervention remains critical for rapid relief of malignant central airway obstruction compared to slower-acting radiation therapy.

Highlights the critical collaboration between interventional pulmonologists and thoracic surgeons for precise localization of small nodules prior to sublobar resection.

Dynamic Cell Imaging is a feasible point-of-care tool for interventional pulmonologists that shows high concordance with final pathology, achieving an overall biopsy-level concordance of 84% (95% CI: 77% to 90%), particularly when paired with cryobiopsies and forceps biopsies.

The VSTAT instruments provide a reliable and objective method for assessing BLVR competency, demonstrating significant score increases across experience tiers (P < 0.001) that should be integrated into training and credentialing pathways.

Endobronchial oxymetazoline is associated with a mild increase in blood pressure and a decrease in heart rate, including a statistically significant increase in bradycardia (OR 1.92, 95% CI 1.09 to 3.40, P = 0.024), but it appears safe and well-tolerated without increasing the need for rescue medications.